• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • Buyouts

ArchiMed buys Stragen Pharma

  • Harriet Matthews
  • Harriet Matthews
  • 25 June 2021
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

ArchiMed has acquired a majority stake in Switzerland-based Stragen Pharma, a company that produces generic drugs for complex and life-threatening illnesses.

ArchiMed said in a statement that current CEO Jean-Luc Tétard is to step down from his role following the deal, but will continue to hold a role on the board. Amine Achite, the former CEO of EA Pharma, will take on the role of CEO.

The GP aims to support the company in developing its product portfolio and intends to invest in its existing operations.

The deal is the fourth platform investment from Med Platform I, which held a final close in August 2020 on €1bn, surpassing its €800m target. The vehicle will be two-thirds committed following the deal.

While the GP's Med I and Med II funds focus on small-cap deals, Med Platform I is its largest vehicle raised to date and targets mid-cap healthcare companies valued at more than €100m. The fund can deploy equity tickets of €50-500m and aims to make six platform investments, with the aim of pursuing buy-and-build strategies to double the size of the businesses during the investment period.

Unquote sister publication Mergermarket reported in May 2020 that Stragen Pharma was up for sale, advised by Cantor Fitzgerald. The company generated EBITDA in the €7-10m range and €60-70m in revenues. Sources told Mergermarket that GPs with healthcare experience could look at the business, including Ardian, Gilde Healthcare Partners, Advent International and Apax Partners.

Company
Founded in 1990, Stragen Pharma specialises in the production of generic drugs for complex and life-threatening illnesses, often producing drugs required by patients in intensive care. The company also produces a range of consumer health products and original drugs. Stragen produces 40 products in total, which are sold in around 60 countries.

Stragen posts revenues of €70m and is headquartered in Geneva.

People
Stragen Pharma – Jean-Luc Tétard (founder); Amine Achite (CEO).
ArchiMed – Jean-Yves Desmottes (partner); André-Michel Ballester (managing partner).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Buyouts
  • DACH
  • Healthcare
  • Switzerland
  • Archimed

More on Buyouts

Permira to take Ergomed private for GBP 703m
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • Buyouts
  • 04 September 2023
Main Capital's Assessio to be sold to Pollen Street
Main Capital's Assessio to be sold to Pollen Street

Recruitment software company tripled in revenue under Main Capital’s ownership

  • Buyouts
  • 25 August 2023
TPG takes majority control of A-Gas, doubles down on impact investing
TPG takes majority control of A-Gas, doubles down on impact investing

KKR partially exits its 2017 investment in the specialty gas and chemical distributor, retaining a minority stake

  • Buyouts
  • 18 August 2023
Quadrivio to capitalise on baby boomers as it nears wrap for its new EUR 300m fund
Quadrivio to capitalise on baby boomers as it nears wrap for its new EUR 300m fund

The Silver Economy Fund makes its second investment as it highlights trend of GPs doubling down on narrow strategies

  • Buyouts
  • 16 August 2023

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013